Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon

Abid R. Assali, Stefano Sdringola, Mohammad Ghani, Ali E. Denkats, Armando Yepes, George P. Hanna, George Schroth, Ken Fujise, H. Vernon Anderson, Richard W. Smalling, Oscar R. Rosales*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Abstract

Percutaneous intervention in acute myocardial infarction has been associated with a high incidence of 'no reflow,' ranging from 11% to 30%, with an increased risk of complications. The role of intracoronary adenosine for the prevention of this phenomenon has not been evaluated fully. We studied the procedural outcomes of 79 patients who underwent percutaneous intervention in the context of acute myocardial infarction. Twenty-eight patients received no intracoronary adenosine, and 51 received intracoronary adenosine boluses (24-48 μg before and after each balloon inflation). Eight patients who were not given adenosine experienced no reflow (28.6%) and higher rates of in-hospital death, while only three of 51 patients (5.9%; P =0.014) in the adenosine group experienced no reflow. No untoward complications were noted during adenosine infusion. Intracoronary adenosine bolus administration during percutaneous intervention in the context of acute myocardial infarction is easy and safe and may significantly lessen the incidence of no reflow, which may improve the outcome of this procedure. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalCatheterization and Cardiovascular Interventions
Volume51
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Keywords

  • 'No reflow' phenomenon
  • Intracoronary adenosine
  • Myocardial infarction
  • Percutaneous transluminal coronary angioplasty

Fingerprint

Dive into the research topics of 'Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon'. Together they form a unique fingerprint.

Cite this